These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39172542)

  • 21. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
    PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis.
    Martina V; Tagliabue M; Bruno GA; Bonetti G; Brancaleoni V; Meineri I; Saracco G; Zumpano E; Manieri C; Camanni F
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):175-80. PubMed ID: 9579229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GIP(3-30)NH
    Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
    Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
    Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
    Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients.
    Düğer H; Bostan H; Deryol HY; İmga NN; Uçan B; Çalapkulu M; Hepşen S; Akhanlı P; Gül Ü; Sencar ME; Çakal E; Özdemir Ş; Kızılgül M
    Growth Horm IGF Res; 2022 Dec; 67():101501. PubMed ID: 36166917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis.
    Jørgensen NT; Erichsen TM; Jørgensen MB; Idorn T; Feldt-Rasmussen B; Holst JJ; Feldt-Rasmussen U; Klose M
    Pituitary; 2023 Feb; 26(1):152-163. PubMed ID: 36609655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly.
    Peracchi M; Porretti S; Gebbia C; Pagliari C; Bucciarelli P; Epaminonda P; Manenti S; Arosio M
    Eur J Endocrinol; 2001 Jul; 145(1):R1-4. PubMed ID: 11415859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human GIP(3-30)NH
    Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
    Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GIP(3-30)NH
    Lynggaard MB; Gasbjerg LS; Christensen MB; Knop FK
    Curr Opin Pharmacol; 2020 Dec; 55():31-40. PubMed ID: 33053504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist.
    Lewis JT; Dayanandan B; Habener JF; Kieffer TJ
    Endocrinology; 2000 Oct; 141(10):3710-6. PubMed ID: 11014226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD; Bonert VS; Mirocha JM; Melmed S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of GIP in α-cells and glucagon secretion.
    El K; Campbell JE
    Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth.
    Buhren BA; Gasis M; Thorens B; Müller HW; Bosse F
    J Neurosci Res; 2009 Jun; 87(8):1858-70. PubMed ID: 19170165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study.
    Jørgensen JO; Rosenfalck AM; Fisker S; Nyholm B; Fineman MS; Schmitz O; Madsbad S; Holst JJ; Christiansen JS
    Eur J Endocrinol; 2000 Nov; 143(5):593-9. PubMed ID: 11078982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load.
    Atquet V; Alexopoulou O; Maiter D
    Eur J Endocrinol; 2021 Jul; 185(2):313-321. PubMed ID: 34085950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions.
    Hage M; Kamenický P; Chanson P
    Neuroendocrinology; 2019; 108(3):244-255. PubMed ID: 30685760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.